The GA-map® Dysbiosis Test Lx
Your front-end solution to microbiota profiling
The GA-map® Dysbiosis test is a valuable tool as a supplement for patient treatment and in clinical research. The test makes it possible to generate profiles of a person’s gut microbiota and connect the profile to the patients’ health conditions. The test is suitable when treating patients with IBS, IBD, diabetes type 2, gut disorder (gastrointestinal problems), lifestyle diseases and leaky-gut syndrome.
The GA-map® Dysbiosis Test Lx is valuable for:
• Clinical researchers
• PCR laboratories
- No inhouse needed – we do the analysis for you and give you back the results for easy interpretation, including bioinformatic resources upon agreement
- An easy and useful tool in patient treatments of IBS, IBD, diabetes type 2, lifestyle diseases, leaky gut syndrome and other gut disorders
- The GA-map® Dysbiosis test is reproducible, standardized, and fast
- An increasing number of researchers have discovered the efficiency and simplicity of using the GA-map® Dysbiosis Test in gut microbiota analysis
- Customized dysbiosis index after your needs
About the product:
Genetic Analysis has developed a CE-marked probe based gut microbiota test on the Luminex® 200 instrument. The technology takes advantage of nucleotide differences in the bacterial 16S rRNA gene to identify predetermined targets. The GA-map® Dysbiosis Test Lx is fully validated according to the IVD directive 98/79/EC and is the first CE-marked IVD test on the market providing microbiota profiles and dysbiosis status in IBS and IBD patients. The method can be set up in any PCR laboratory or samples can be shipped to our service laboratory in Oslo, Norway.
Our service laboratory in Oslo, Norway will provide you the stool sampling kit, analyze the samples, and send back your results.
Reference population comparison
The bacteria abundance from your test is compared to our normal reference population. The GA-map® analyzer software algorithm calculates the degree of dysbiosis in the sample.
The performance of the GA-map® test/technology is well documented through extensive verification and validation. The standardization and documentation of the GA-map® Test ensures highly reproducible results.
ISO certified and CE-marked
Genetic Analysis is an ISO 13485:2016 certified company. The GA-map® Dysbiosis Test Lx is CE-marked in Europe and the GA-map® is available for research in the US.
The GA-map® Dysbiosis Test is clinical validated through cohorts of subjects with normal gut microbiota and patients with IBS and IBD. Further, the test has been used in a number of clinical studies on numerus patient cohorts published in peer reviewed journals. (Link to publications). Hence, the GA-map® Dysbiosis Test is standardized and documented for clinical use.
Interpretation of the result from the GA-map®Dysbiosis Test
All pre-processing of the data is done by the GA-map® Dysbiosis Test analyze software. The test reports are automatically generated on the dysbiosis index (DI) and the bacteria abundance. The DI can be customized to your needs. Based on a deviation from a normal reference population, a measure of bacteria abundances and deviations to the references are calculated. The results are presented in an easy to interpret report form, containing the 48 preselected bacteria markers.